KCCOP Protocol Summary

 Home | Print Summary

The summary below serves as a brief review of the treatment plan and eligibility for the protocol.
This summary is not intended to be used in place of the full protocol.
Members may follow the "Full Protocol" link or contact KCCOP for complete protocol information.

 

 Full Protocol

(members only)

 

Consent Form 

 

HIPAA

 

Spanish Consent Form

CTSU ACOSOG Z1031 - "A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg), or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer"

 

Treatment Plan    (Supplied Drug:  None)

 

Arm 1

Exemestane:  25mg/day, PO, x 16-18 wks (followed by surgery)

Arm 2

Letrozole:  2.5mg/day, PO, x 16-18 wks (followed by surgery)

Arm 3

Anastrozole:  1mg/day, PO, x 16-18 wks (followed by surgery)

 â

SURGERY

 â

Follow x 10 yrs.  Continue Anastrozole or Tamoxifen x 5 yrs at physician's discretion.

 

Eligibility